Alkermes (ALKS) is trading up at $44.18 (+1.61%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Alkermes revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $745.7M | $903.4M | $1.09B | $1.17B | $1.04B | $1.17B | $1.11B | $1.66B | $1.56B | $1.48B |
| Growth (year over year) | +18.7% | +21.1% | +21.1% | +7.0% | −11.3% | +13.0% | −5.3% | +49.6% | −6.4% | −5.2% |
| Gross profit | $613.6M | $748.6M | $917.9M | $990.6M | $860.4M | $976.4M | $893.7M | $1.41B | $1.31B | $1.28B |
| Gross margin | 82.3% | 82.9% | 83.9% | 84.6% | 82.8% | 83.2% | 80.4% | 84.8% | 84.2% | 86.7% |
| Operating income | −$208.7M | −$147.9M | −$99.1M | −$175.5M | −$112.4M | $97.7M | −$6.09M | $414.1M | $420.6M | $254.0M |
| Operating margin | −28.0% | −16.4% | −9.1% | −15.0% | −10.8% | 8.3% | −0.5% | 24.9% | 27.0% | 17.2% |
| Net income | −$208.4M | −$157.9M | −$139.3M | −$196.6M | −$110.9M | −$48.2M | −$158.3M | $355.8M | $367.1M | $241.7M |
| Net margin | −28.0% | −17.5% | −12.7% | −16.8% | −10.7% | −4.1% | −14.2% | 21.4% | 23.6% | 16.4% |
| EPS (diluted) | −$1.38 | −$1.03 | −$0.90 | −$1.25 | −$0.70 | −$0.29 | −$0.97 | $2.10 | $2.17 | $1.43 |
| Balance sheet | ||||||||||
| Cash and equivalents | $186.4M | $191.3M | $266.8M | $203.8M | $273.0M | $337.5M | $292.5M | $457.5M | $291.1M | $388.6M |
| Total assets | $1.73B | $1.80B | $1.83B | $1.81B | $1.95B | $2.02B | $1.96B | $2.14B | $2.06B | $2.49B |
| Total liabilities | $516.9M | $594.4M | $653.7M | $720.0M | $882.7M | $911.9M | $920.2M | $933.5M | $590.6M | $667.7M |
| Long-term debt | $280.7M | $278.4M | $276.5M | $274.3M | $272.1M | $292.8M | $290.3M | $287.7M | — | $0 |
| Shareholders' equity | $1.21B | $1.20B | $1.17B | $1.09B | $1.07B | $1.11B | $1.04B | $1.20B | $1.46B | $1.82B |
| Cash flow | ||||||||||
| Operating cash flow | −$63.8M | $19.2M | $99.3M | $72.1M | $82.8M | $101.7M | $21.0M | $401.4M | $439.1M | $520.8M |
| Capital expenditure | $43.7M | $51.3M | $69.4M | $90.9M | $42.2M | $28.0M | $38.3M | $48.0M | $33.5M | $40.4M |
| Free cash flow | −$107.5M | −$32.1M | $29.9M | −$18.9M | $40.6M | $73.7M | −$17.2M | $353.3M | $405.6M | $480.3M |
| Share buybacks | — | — | — | — | — | — | — | — | $200.3M | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $378.1M | $430.0M | $306.5M | $390.7M | $394.2M | $384.5M | $392.9M | $496.0M |
| Growth (year over year) | −0.7% | +13.9% | −12.5% | −2.1% | +4.2% | −10.6% | +28.2% | +27.0% |
| Gross profit | $315.0M | $367.9M | $257.3M | $341.2M | $342.6M | $338.3M | $331.3M | $397.9M |
| Gross margin | 83.3% | 85.6% | 83.9% | 87.3% | 86.9% | 88.0% | 84.3% | 80.2% |
| Operating income | $104.8M | $162.7M | $13.8M | $93.0M | $89.1M | $58.1M | −$48.3M | $18.4M |
| Operating margin | 27.7% | 37.8% | 4.5% | 23.8% | 22.6% | 15.1% | −12.3% | 3.7% |
| Net income | $92.4M | $146.5M | $22.5M | $87.1M | $82.8M | $49.3M | −$66.5M | $501.0K |
| Net margin | 24.4% | 34.1% | 7.3% | 22.3% | 21.0% | 12.8% | −16.9% | 0.1% |
| EPS (diluted) | $0.55 | $0.88 | $0.13 | $0.52 | $0.49 | $0.29 | −$0.40 | $0.00 |
| Balance sheet | ||||||||
| Cash and equivalents | $396.3M | $291.1M | $399.8M | $521.2M | $616.4M | $388.6M | $351.6M | $511.5M |
| Total assets | $2.16B | $2.06B | $2.08B | $2.25B | $2.33B | $2.49B | $4.26B | $4.39B |
| Total liabilities | $863.2M | $590.6M | $570.4M | $628.2M | $596.1M | $667.7M | $2.51B | $2.58B |
| Long-term debt | $285.8M | — | — | — | — | $0 | $1.48B | $1.48B |
| Shareholders' equity | $1.29B | $1.46B | $1.51B | $1.62B | $1.73B | $1.82B | $1.75B | $1.81B |
| Cash flow | ||||||||
| Operating cash flow | $81.6M | $190.4M | $98.8M | $150.2M | $101.7M | $170.1M | −$165.7M | $145.2M |
| Capital expenditure | $8.26M | $9.77M | $10.1M | $13.0M | $17.3M | −$20.0K | $4.09M | $8.15M |
| Free cash flow | $73.3M | $180.6M | $88.7M | $137.2M | $84.4M | $170.1M | −$169.8M | $137.0M |
| Share buybacks | $115.6M | $1.00K | — | — | — | — | $27.7M | $0 |
From Alkermes's 10-K, 10-KT and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Alkermes
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.
Source: Wikipedia — Alkermes plc
- Headquarters
- Dublin, Ireland From SEC filings, Oct 2026
Recent News (2)
-
Goldman Sachs resumes Alkermes stock coverage with neutral rating
Goldman Sachs resumes Alkermes stock coverage with neutral rating
-
Unusual Options Activity: ALKS, TSLA and Others Attract Market Bets, ALKS V/OI Ratio Reaches 178.1 Unusual Options Activity: ALKS, TSLA and Others Attract Market Bets, ALKS V/OI Ratio Reaches 178.1 Moomoo
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International